肺癌靶向治療的更為高效的藥物出現了。諾華研發的Ceritinib是一種ALK (anaplastic lymphoma kinase) 抑製劑，體外試驗顯示，其ALK抑製效能高出克裏唑蒂尼(crizotinib)20倍。今天出版的新英格蘭醫學雜誌 (NEJM) 發表了Ceritinib 的臨床1期研究結果：對克裏唑蒂尼耐藥的ALK-重排NSCLC患者，服用Ceritinib後所產生的治療應答率高達56%。
論文鏈接: A More Potent ALK Inhibitor in Lung Cancer
March 27, 2014 | A.T. Shaw and Others
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in 56% of those who had resistance to crizotinib.
肺癌分類圖
新藥的四期臨床試驗(從下往上看~.~)
